Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Celia Morton"'
1
2013. Bloodstream Infections in Advanced Heart Failure Patients Requiring Prolonged Use of Axillary Intra-Aortic Balloon Pumps - A Single Center Study
Autor: Diane Dreucean, Kevin R Donahue, Celia Morton, Luma Succar, Jill Krisl, Tanushree Agrawal, Katherine K Perez, Taylor Jaramillo, Mahwash Kassi, Rayan Yousefzai, Imad Hussain, Ashrith Guha, Ju Kim, Arvind Bhimaraj
Publikováno v: Open Forum Infectious Diseases. 9
Background Bloodstream infections (BSI) impact outcomes in critically ill patients. Institutions and quality and performance improvement efforts to minimize catheter associated infections are valued to optimize outcomes. While intra-aortic balloon pu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25f318d4930a84efd5b0bff9af31ddc6
https://doi.org/10.1093/ofid/ofac492.1637
Zobrazit plný text záznamu
2
Anticoagulation in COVID-19: a review of current literature and guidelines
Autor: Christopher Perez Lizardo, Bharat Narasimhan, Kevin R. Donahue, Celia Morton, Marta Lorente-Ros, Jose S Aguilar-gallardo, Harish Narasimhan, Wilbert S. Aronow
Publikováno v: Hospital Practice. 49:307-324
Severe acute respiratory syndrome coronavirus 2 infections are associated with greater risk of both arterial and venous thromboembolic events. This has been attributed to a florid pro-inflammatory state resulting in microvascular dysfunction, activat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20f9a10cad5389a24d9de8d0740f15e0
https://doi.org/10.1080/21548331.2021.2007648
Zobrazit plný text záznamu
3
Outcomes Associated With 4‐Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients
Autor: Annette Lista, Celia Morton, Emily A. Highsmith, Kevin R. Donahue, Sara Varnado, Suraj Sulhan
Publikováno v: The Journal of Clinical Pharmacology. 61:598-605
Compared with vitamin K antagonists (VKAs), oral factor Xa inhibitors are associated with at least equivalent efficacy and a lower incidence of major bleeding. Despite this benefit, bleeding remains the most common adverse event. Prior to the approva
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f83ac1741d03e7e3f921378828630f3a
https://doi.org/10.1002/jcph.1779
Zobrazit plný text záznamu
4
Comparison of Sedation and Analgesia Requirements in Patients With SARS-CoV-2 Versus Non-SARS-CoV-2 Acute Respiratory Distress Syndrome on Veno-Venous ECMO
Autor: Mariah I. Sigala, Diane Dreucean, Jesse E. Harris, Kevin R. Donahue, Fariedeh Bostan, Prakruthi Voore, Jose Cuevas, Celia Morton
Publikováno v: Annals of Pharmacotherapy. :106002802211476
Background: Increased analgosedation requirements have been described in patients with acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO) support due to unique pharmacokinetic challenges. There is a paucity of da
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9ab4da429e835899e0f93bddadcc06e2
https://doi.org/10.1177/10600280221147695
Zobrazit plný text záznamu
6
Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series
Autor: Annette Lista, Eric Salazar, Nicholas Jakowenko, Kevin R. Donahue, Celia Morton
Publikováno v: Journal of thrombosis and thrombolysis. 53(1)
Andexanet alfa, a modified recombinant factor Xa (FXa), was FDA approved in 2018 for anticoagulant reversal in patients with life-threatening bleeding associated with FXa inhibitors (FXaI). The ANNEXA-4 investigators administered andexanet alfa to pa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd1dd972f5021503237ef09134f766d
https://pubmed.ncbi.nlm.nih.gov/34236614
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje